vs
Montrose Environmental Group, Inc.（MEG）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
Montrose Environmental Group, Inc.的季度营收约是再鼎医药的1.5倍（$193.3M vs $127.1M），再鼎医药同比增速更快（17.1% vs 2.2%），Montrose Environmental Group, Inc.自由现金流更多（$46.5M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 11.5%）
蒙特罗斯环境集团是一家美国跨国企业，主营各类环境服务，业务覆盖环境行业全产业链，可为公共部门及私营领域客户提供一体化支持。公司总部位于阿肯色州小石城，在美国特拉华州完成注册。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
MEG vs ZLAB — 直观对比
营收规模更大
MEG
是对方的1.5倍
$127.1M
营收增速更快
ZLAB
高出14.9%
2.2%
自由现金流更多
MEG
多$73.2M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
11.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $193.3M | $127.1M |
| 净利润 | $-8.2M | — |
| 毛利率 | 38.6% | 51.0% |
| 营业利润率 | -1.3% | -54.6% |
| 净利率 | -4.3% | — |
| 营收同比 | 2.2% | 17.1% |
| 净利润同比 | 70.9% | — |
| 每股收益（稀释后） | $-0.13 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MEGZLAB
| Q4 25 | $193.3M | $127.1M | ||
| Q3 25 | $224.9M | $115.4M | ||
| Q2 25 | $234.5M | $109.1M | ||
| Q1 25 | $177.8M | $105.7M | ||
| Q4 24 | $189.1M | $108.5M | ||
| Q3 24 | $178.7M | $101.8M | ||
| Q2 24 | $173.3M | $100.1M | ||
| Q1 24 | $155.3M | $87.1M |
净利润MEGZLAB
| Q4 25 | $-8.2M | — | ||
| Q3 25 | $8.4M | $-36.0M | ||
| Q2 25 | $18.4M | $-40.7M | ||
| Q1 25 | $-19.4M | $-48.4M | ||
| Q4 24 | $-28.2M | — | ||
| Q3 24 | $-10.6M | $-41.7M | ||
| Q2 24 | $-10.2M | $-80.3M | ||
| Q1 24 | $-13.4M | $-53.5M |
毛利率MEGZLAB
| Q4 25 | 38.6% | 51.0% | ||
| Q3 25 | 39.4% | 59.5% | ||
| Q2 25 | 43.4% | 60.6% | ||
| Q1 25 | 39.0% | 63.6% | ||
| Q4 24 | 40.8% | 61.5% | ||
| Q3 24 | 40.9% | 64.1% | ||
| Q2 24 | 39.9% | 64.9% | ||
| Q1 24 | 37.8% | 61.4% |
营业利润率MEGZLAB
| Q4 25 | -1.3% | -54.6% | ||
| Q3 25 | 4.4% | -42.3% | ||
| Q2 25 | 6.4% | -50.3% | ||
| Q1 25 | -5.9% | -53.3% | ||
| Q4 24 | -12.1% | -62.6% | ||
| Q3 24 | -0.6% | -66.6% | ||
| Q2 24 | -1.5% | -76.0% | ||
| Q1 24 | -6.5% | -80.7% |
净利率MEGZLAB
| Q4 25 | -4.3% | — | ||
| Q3 25 | 3.7% | -31.2% | ||
| Q2 25 | 7.8% | -37.3% | ||
| Q1 25 | -10.9% | -45.8% | ||
| Q4 24 | -14.9% | — | ||
| Q3 24 | -5.9% | -40.9% | ||
| Q2 24 | -5.9% | -80.2% | ||
| Q1 24 | -8.6% | -61.4% |
每股收益（稀释后）MEGZLAB
| Q4 25 | $-0.13 | $-0.05 | ||
| Q3 25 | $0.21 | $-0.03 | ||
| Q2 25 | $0.42 | $-0.04 | ||
| Q1 25 | $-0.64 | $-0.04 | ||
| Q4 24 | $-0.91 | $-0.09 | ||
| Q3 24 | $-0.39 | $-0.04 | ||
| Q2 24 | $-0.39 | $-0.08 | ||
| Q1 24 | $-0.53 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.2M | $689.6M |
| 总债务越低越好 | $277.1M | — |
| 股东权益账面价值 | $451.2M | $715.5M |
| 总资产 | $981.3M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.61× | — |
8季度趋势，按日历期对齐
现金及短期投资MEGZLAB
| Q4 25 | $11.2M | $689.6M | ||
| Q3 25 | $6.7M | $717.2M | ||
| Q2 25 | $10.5M | $732.2M | ||
| Q1 25 | $30.3M | $757.3M | ||
| Q4 24 | $12.9M | $779.7M | ||
| Q3 24 | $13.0M | $616.1M | ||
| Q2 24 | $16.9M | $630.0M | ||
| Q1 24 | $9.5M | $650.8M |
总债务MEGZLAB
| Q4 25 | $277.1M | — | ||
| Q3 25 | $302.4M | — | ||
| Q2 25 | $264.6M | — | ||
| Q1 25 | $235.6M | — | ||
| Q4 24 | $204.8M | — | ||
| Q3 24 | $233.0M | — | ||
| Q2 24 | $188.7M | — | ||
| Q1 24 | $280.9M | — |
股东权益MEGZLAB
| Q4 25 | $451.2M | $715.5M | ||
| Q3 25 | $458.7M | $759.9M | ||
| Q2 25 | $470.3M | $791.7M | ||
| Q1 25 | $444.1M | $810.8M | ||
| Q4 24 | $446.3M | $840.9M | ||
| Q3 24 | $449.2M | $667.7M | ||
| Q2 24 | $448.8M | $704.2M | ||
| Q1 24 | $324.5M | $762.2M |
总资产MEGZLAB
| Q4 25 | $981.3M | $1.2B | ||
| Q3 25 | $985.7M | $1.2B | ||
| Q2 25 | $998.1M | $1.2B | ||
| Q1 25 | $992.2M | $1.2B | ||
| Q4 24 | $990.4M | $1.2B | ||
| Q3 24 | $1.0B | $985.3M | ||
| Q2 24 | $943.9M | $987.4M | ||
| Q1 24 | $918.1M | $988.4M |
负债/权益比MEGZLAB
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.42× | — | ||
| Q1 24 | 0.87× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $51.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $46.5M | $-26.7M |
| 自由现金流率自由现金流/营收 | 24.1% | -21.0% |
| 资本支出强度资本支出/营收 | 2.8% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.2M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流MEGZLAB
| Q4 25 | $51.9M | $-26.0M | ||
| Q3 25 | $28.1M | $-32.0M | ||
| Q2 25 | $21.9M | $-31.0M | ||
| Q1 25 | $5.5M | $-61.7M | ||
| Q4 24 | $32.0M | $-55.8M | ||
| Q3 24 | $11.4M | $-26.8M | ||
| Q2 24 | $894.0K | $-42.2M | ||
| Q1 24 | $-22.0M | $-90.1M |
自由现金流MEGZLAB
| Q4 25 | $46.5M | $-26.7M | ||
| Q3 25 | $22.3M | $-35.0M | ||
| Q2 25 | $19.9M | $-33.9M | ||
| Q1 25 | $2.4M | $-63.2M | ||
| Q4 24 | $29.7M | $-58.4M | ||
| Q3 24 | $10.2M | $-28.2M | ||
| Q2 24 | $-9.8M | $-42.9M | ||
| Q1 24 | $-29.3M | $-91.1M |
自由现金流率MEGZLAB
| Q4 25 | 24.1% | -21.0% | ||
| Q3 25 | 9.9% | -30.4% | ||
| Q2 25 | 8.5% | -31.1% | ||
| Q1 25 | 1.3% | -59.9% | ||
| Q4 24 | 15.7% | -53.8% | ||
| Q3 24 | 5.7% | -27.7% | ||
| Q2 24 | -5.6% | -42.9% | ||
| Q1 24 | -18.9% | -104.5% |
资本支出强度MEGZLAB
| Q4 25 | 2.8% | 0.5% | ||
| Q3 25 | 2.6% | 2.6% | ||
| Q2 25 | 0.8% | 2.6% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 1.2% | 2.4% | ||
| Q3 24 | 0.6% | 1.3% | ||
| Q2 24 | 6.1% | 0.7% | ||
| Q1 24 | 4.7% | 1.1% |
现金转化率MEGZLAB
| Q4 25 | — | — | ||
| Q3 25 | 3.36× | — | ||
| Q2 25 | 1.19× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MEG
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
